Kornimate/medical-research-clean huggingface dataset:
smog induced indoor air pollution in homes of chronic obstructive pulmonary disease patients.

Conditions: Chronic Obstructive Pulmonary Disease

Summary: primary objective of this project is to measure the impact of passive control and active control systems on indoor pollution that is directly or indirectly related to ambient air pollution (smog). the first goal will be to measure baseline parameters for 50 homes, including information about the building, ventilation characteristics, pollution levels (indoors and outdoors), and occupant survey information. in a subset of these homes, either passive or active control systems will be installed and the impact of these systems on indoor concentrations. participants will be enrolled on a rolling basis (5-15 persons studied at a given point in time) over a 16-month period. participants will be followed for approximately 5 weeks and data obtained at three points in time: at enrollment (day 1 of study), after 1 week (baseline verification) and after four weeks with the control system in the home (at the end of study week 5).

chronic obstructive pulmonary disease (copd) is a degenerative lung disease resulting in lower lung function characterized by an obstruction to airflow. copd is an umbrella term for two disease processes: chronic bronchitis and emphysema. it is currently the 4th leading cause of death in the united states. approximately 14 million americans are known to suffer from copd; however, it is estimated that as many as 24 million americans may have some form of one or both of the diseases (centers for disease control, 2011). the primary risk factor for developing copd is cigarette smoking; other factors include exposure to air pollution, occupational dusts and chemicals, and lower socioeconomic status. poverty has been identified as a risk factor for copd but the aspects related to poverty that increase the risk of copd are unclear (gold, 2011). lower education level and household income has been noted to relate to increased severity of copd (eisner, blanc, omachi, yelin, sidney, katz, et al, 2011). an american lung association survey found that over half of those diagnosed with copd reported that their condition limits their ability to perform activities of daily living, including activities in the home (american lung association, 2009). as air pollution can lead to an exacerbation of copd symptoms and precipitate emergency room visits and hospitalization, minimizing pollution in indoor air may be a key component of disease management and decreasing health care costs.

Eligibility criteria:
inclusion criteria: * diagnosis of copd (stage iii or iv); adults over the age of 18 years exclusion criteria: * children (persons under age 18), fetuses, neonates, pregnant women, prisoners

Keywords: copd air quality
trial of scrambler therapy or sham treatment for low back pain

Conditions: Low Back Pain

Summary: this pilot study will evaluate scrambler therapy and sham treatment on levels of low back pain, pain sensitivity and mrna expression of pain sensitivity candidate genes.

this pilot study will evaluate the feasibility of the experimental protocol and provide sufficient pilot data to estimate statistical power and sample size requirements. the study will include 30 individuals (15 per group) diagnosed with persistent low back pain who will receive a standard protocol of scrambler therapy or sham treatment. participant data will include subjective measures of low back pain, pain sensitivity using quantitative sensory testing, and mrna expression levels of pain sensitivity candidate genes at baseline (prior to treatment) and 1 and 3 weeks post-treatment.

Eligibility criteria:
inclusion criteria: * be 18-50 years of age * diagnosed with persistent nonspecific lbp * comprehend english exclusion criteria: * \ 50 years of age * chronic pain at another site or associated with a painful condition * pregnant or within 3 months post-partum * implanted drug delivery system * heart stents or metal implants such as pacemakers, automatic defibrillator, aneurysm clips, vena cave slips, or skull plates * history of myocardial infarction or ischemic heart disease within the past six months * history of epilepsy * skin conditions such as open sores that would prevent proper application of electrodes

Keywords: nonspecific low back pain chronic low back pain
a study of the efficacy and safety of asenapine in participants with an acute exacerbation of schizophrenia (p05688)

Conditions: Schizophrenia

Summary: the purpose of this trial is to assess the effect of asenapine 2.5 and 5 mg sublingually twice daily (bid) compared with placebo in the treatment of schizophrenia (overall symptoms) as measured by the positive and negative syndrome scale (panss). olanzapine administered 15 mg orally once daily (qd) was used as an active control. the primary hypothesis is that at least one of the asenapine doses is superior to placebo in improving schizophrenia symptoms as measured by the change from baseline in the panss total score at day 42. the first key secondary hypothesis is that at least one of the asenapine doses is superior to placebo in improving schizophrenia symptoms as measured by the change from baseline in clinical global impression scale-severity (cgi-s) score at day 42. the second key secondary hypothesis is that at least one of the asenapine doses is superior to placebo in improving schizophrenia symptoms as measured by the rate of panss responders (≥30% reduction from baseline in panss total score) at day 42.

the trial consists of a screening/tapering period, treatment period, and follow-up period. the 6-week active treatment period includes an inpatient phase and outpatient phase. participants who complete the trial may continue treatment under a long-term extension protocol (p05689). participants who do not continue in the treatment continuation trial (whether they complete the 6-week trial or discontinue prematurely) will have a follow-up visit 7 days after their last dose of trial medication.

Eligibility criteria:
inclusion criteria: * current diagnosis of schizophrenia of paranoid, disorganized, or undifferentiated subtype * minimum panss total score of 70 at screening and baseline * score of at least 4 (moderate) in two or more of the five items in the positive subscale of the panss * confirmed to be experiencing an acute exacerbation of schizophrenia * cgi-s scale score of at least 4 (moderately ill) at baseline * has responded positively to an antipsychotic medication other than clozapine (clozaril®) in a prior episode exclusion criteria: * body mass index (bmi) \ 40.0 kg/m\^2 * laboratory and/or clinical evidence of clinically significant hepatic conditions * known history of, or undergoing treatment for, narrow angle glaucoma * diagnosed with epilepsy or has had any seizure disorder beyond childhood febrile seizures * known serological evidence of human immunodeficiency virus (hiv) antibody * history of neuroleptic malignant syndrome or tardive dyskinesias * past or current diagnosis of schizoaffective disorder, schizophrenia of residual subtype, schizophrenia of catatonic subtype, current diagnosis of schizophrenia with course specifiers continuous, single episode in partial remission, or single episode in full remission, or borderline personality disorder
simulation training to improve 911 dispatcher identification of cardiac arrest

Conditions: Cardiac Arrest

Summary: this study is to test the use of simulation training to improve 9-1-1 telecommunicators' call processing and response. training sessions will expose 9-1-1 telecommunicators to several realistic emergency situations through mock 9-1-1 calls with a trained actor playing the part of a reporting party, followed immediately by feedback on call handling provided by a trained call observer. investigators hypothesize that simulation followed by trained observer-directed feedback will increase correct triage of medical emergency and delivery of pre-arrival instructions during simulated calls and in actual 9-1-1 calls.


Eligibility criteria:
inclusion criteria: 9-1-1 call-center call receivers. - exclusion criteria: -
investigation of road-crossing safety before and after training between parkinson disease pedestrians and older pedestrians

Conditions: Parkinson's Disease

Summary: as society ages, a large amount of human factors related research has been carried out into the subject of the safety of the elderly in their daily lives. however, most research focuses on the general elderly population and there is a serious lack of research into elderly sufferers of parkinson's disease (pd), who receive a substantial amount of attention in medical circles. in the investigators previous study, the investigators have found that patient with pd had decreased ability to cross the road as compared to age/gender matched control subjects. hence, this research proposed several training programs to enhance the safety of crossing road, including safe place finding，roadside search，time gap and perception of other's intentions. the investigators will compare the parameters of crossing road ability before and after training programs in patients with pd and control subjects. the results of this research will clarify the correlation between medical scale test indicators and movement safety for patients with pd. the effects of training programs will be provided for further safety management and design concepts to improve the lives of this disease group.


Eligibility criteria:
inclusion criteria: * patients with parkinson's disease * age between 18-80 years * patients signed the consent form exclusion criteria: * patients with atypical parkinsonism

Keywords: to asses the training effects on traffic safety between normal and patients with parkinson's disease
assessing cardiovascular dysfunction pre- & post-treatment in inflammatory bowel diseases

Conditions: Inflammatory Bowel Diseases

Summary: the aim of this study is to compare medical and surgery treatment in ibd patients and healthy controls, by assessing the endothelial and cardiac function and the inflammation status.

the aim of this study is to compare medical and surgery treatment in ibd patients and healthy controls, by assessing the endothelial and cardiac function and the inflammation status. in particular, three subject groups will be enrolled, as follows: 40 patients \[crohn's disease (cd) \& ulcerative colitis (uc)\] who will undergo medical treatment (group a), 40 patients (cd \& uc) who will undergo surgery (group b) and a healthy control group (group c) comprising 40 subjects. assessment of the inflammation load (crp, wbc, il-6, tnfa), the endothelial function (fmd, pwv, cimt, endothelial glycocalyx) and the cardiac function - via echocardiographic parameters (systolic and diastolic echo values, tissue doppler imaging-gls-strain rate) - will be carried out for every subject group in two phases: prior to treatment and four months after the treatment, as applicable. the objective is to investigate whether there is a statistically significant reduction of endothelial and cardiac dysfunction following medical and surgery treatment in ibd patients as well as to examine associations across the three groups.

Eligibility criteria:
inclusion criteria: * patients with ibd diagnosed \> 6 months via biopsy confirming the diagnosis * patients with ibd at an advanced \& non-controllable phase (ibd scores,clinical status, endoscopic and biochemical values) requiring the initiation of a new medical treatment or surgical intervention. exclusion criteria: * coronary artery disease * peripheral arterial disease * thromboembolic disease (acute or chronic) * heart failure of any cause * valvular disease * congenital heart defect * heart rhythm disorder * stroke, renal or liver failure, malignancy, endocrine disorder * other autoimmune disorder or angiitis * ibd diagnosed \< 6 months * bmi \> 40 kg/m2
traumacel pulvis and traumacel endo applicator in the post-market surveillance phase

Conditions: Bleeding; Surgical Wound

Summary: traumacel pulvis is a sterile absorbable haemostatic plant polysaccharide powder made of the oxidized cellulose. traumacel pulvis is designed to stop capillary bleeding as well as to prevent bleeding in the early post-operative stage, for example to stop capillary bleeding from resection areas of parenchymatous organs, muscles, to stop bleeding after endoscopy, mainly rectoscopic, procedures. the broadness of application allows for use in procedures performed in the standard way as well as endoscopically. traumacel endo applicator is a single use, flexible, manual apparatus designed to deliver the absorbable haemostatic powder traumacel pulvis. the main objective of this clinical study is to confirm the safety and efficacy of the medical device traumacel pulvis and traumacel endo applicator when used in accordance with their intended purpose. the partial objectives are: to identify potential incompatibilities of traumacel endo applicator with other surgical instruments, in particular with different types of trocar cannulas; for both devices (traumacel endo applicator and traumacel pulvis) the identification and analysis of potential emerging risks; confirmation of the acceptability of the benefit-risk ratio; identification of any systematic misuse of the device or off-label use of the device in order to verify the correctness of its intended purpose.


Eligibility criteria:
inclusion criteria: * minimum age of 18. * surgical intervention. * negative pregnancy test of women in fertile age. * diffuse soft tissue, vascular or parenchymal haemorrhage after conventional surgical haemostatic methods have not worked or are impractical (e.g. ligation, suture, compression, cauterisation). * informed consent. exclusion criteria: * hypersensitivity or a known reaction to oxidized cellulose. * age under 18 * a severe clinical condition of the patient (e.g. associated illness, mental disorder) which, according to the investigator, could adversely affect patient safety and/or compliance with the procedures used in the study. * the patient has participated in another clinical study involving a haemostatic product within 30 days prior to enrolment, or another such clinical study is planned during the subject's participation in the study. * pregnancy or lactation. * if during the procedure itself, there was no need to use the test agent * application of any other topical haemostatic product prior to application of the test agent to the same site.

Keywords: oxidized cellulose haemostatic agent
rebeccamycin analog as second-line therapy in treating patients with limited-stage or extensive-stage small cell lung cancer that relapsed after previous first-line chemotherapy

Conditions: Extensive Stage Small Cell Lung Cancer; Limited Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer

Summary: drugs used in chemotherapy, such as rebeccamycin analog, work in different ways to stop tumor cells from dividing so they stop growing or die. this phase ii trial is studying how well rebeccamycin analog works as second-line therapy in treating patients with limited-stage or extensive-stage small cell lung cancer that has relapsed after previous first-line chemotherapy.

objectives: i. determine the objective response rate in patients with limited or extensive stage small cell lung cancer that relapsed after prior first-line chemotherapy when treated with rebeccamycin analogue as second-line therapy. ii. determine the duration of remission and survival of patients treated with this drug. iii. determine the toxicity of this drug in these patients. outline: this is a multicenter study. patients receive rebeccamycin analogue iv over 1 hour on days 1-5. treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. patients are followed annually. projected accrual: a total of 20-39 patients will be accrued for this study within 15 months.

Eligibility criteria:
inclusion criteria: * diagnosis of small cell lung cancer (sclc) * limited or extensive stage * at least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques or at least 10 mm by spiral ct scan * sensitive\* relapsed disease after only 1 prior chemotherapy regimen * brain metastasis allowed provided the following criteria are met: * stable brain disease * not receiving irradiation * no steroid requirement to control symptoms * performance status - ecog 0-2 * performance status - karnofsky 60-100% * at least 12 weeks * absolute neutrophil count ≥ 1,500/mm\^3 * platelet count ≥ 100,000/mm\^3 * hemoglobin ≥ 9.0 g/dl * ast and alt \< 2.5 times upper limit of normal (uln) (5 times uln if liver involvement is present) * bilirubin ≤ 1.5 mg/dl * creatinine \< 2.0 mg/dl * creatinine clearance ≥ 60 ml/min * no new york heart association class iii or iv heart disease * no symptomatic congestive heart failure * no unstable angina pectoris * no cardiac arrhythmia * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * no active or ongoing infection * no other concurrent uncontrolled illness * no psychiatric illness or social situation that would preclude study compliance * see disease characteristics * see disease characteristics * see disease characteristics * prior radiotherapy allowed * no other concurrent investigational agents * no other concurrent therapies for sclc * no concurrent combination antiretroviral therapy for hiv-positive patients
preemptive co-infiltration of triamcinolone acetonide with ropivacaine for postoperative pain in major spinal surgery

Conditions: Pain; Postoperative

Summary: patients undergoing major spinal surgery usually experience moderate to-severe postoperative pain. inadequate pain control may lead to severe complications. local infiltration analgesia (lia) with a local anesthetic, is a simple, minimally invasive, and effective postoperative pain management technique. however, lia with local anesthetic alone can only last for a short time, steroid as adjuvant can enhance postoperative analgesia and prolong postoperative analgesia time. triamcinolone acetonide as an adjunctive infiltration to local anesthesia presented a superior analgesic benefit compared with local anesthesia alone in various types of surgeries. to date, no studies have evaluated the additive analgesia effects of triamcinolone acetonide on incision infiltration in major spinal surgery. the purpose of this trial is to determine whether preemptive co-infiltration of triamcinolone acetonide and ropivacaine in surgical incision will further reduce postoperative opioid requirements and pain score after spinal surgery than that of ropivacaine alone.


Eligibility criteria:
inclusion criteria: age 18-65 years; patients scheduled for elective laminoplasty or laminectomy with no more than 3 levels under general anesthesia; american society of anesthesiologists (asa) physical status of i-iii; anticipated full recovery and cooperation within 2 hours postoperatively. exclusion criteria: history of spinal surgery; inability to use a patient-controlled analgesia (pca) pump or comprehend the pain visual analog scale (vas); body mass index (bmi)\ 35kg/m2; peri-incisional infection; history of diabetes mellitus and other metabolic diseases; history of severe cardiopulmonary, hepatic or renal dysfunction; preoperative coagulation abnormalities (activated partial thromboplastin time greater than 1.5 times normal value); history of allergies to any of the study drugs; history of alcohol or drugs abuse (more than 2 weeks), or use of any analgesic within 24h before surgery; use of systemic steroids within 1 week before surgery; history of psychiatric disorders, chronic neck or back pain; history of radiation therapy and chemotherapy or with a high probability of such treatment postoperatively; pregnant or breastfeeding; refusal to sign informed consent.
retorna facial cream in the treatment of facial wrinkles

Conditions: Facial Wrinkles

Summary: the purpose of the study is to assess the efficacy of retorna facial cream usage in the reduction or total correction of facial wrinkles. the duration of this double-blind placebo controlled phase 3 clinical trial will be 4 weeks. the estimated number of women to be recruited and randomized for the study is 148. occurrence of adverse effects will also be evaluated.


Eligibility criteria:
inclusion criteria: * facial wrinkles * signed informed consent * given verbal agreement on solar exposure prevention within hours of intense solar radiation (10 am - 4 pm) by the usage of physical protection methods such as umbrellas, caps and hats. exclusion criteria: * pregnancy * breast-feeding * use of steroids within 6 months. * patients under other experimental treatment * decompensated concomitant diseases * malignant neoplastic conditions. * alcoholism * handicap and/or psychiatric condition preventing treatment accomplishment.

Keywords: facial cream natural product facial wrinkles
osa (orisk of obstructive sleep apnea and traffic accidents among bus drivers in ecuador: is there a significant association

Conditions: Sleep Apnea, Obstructive

Summary: our study aims to determine the frequency of individuals at high risk of obstructive sleep apnea, and excessive daytime sleepiness, as well as any potential association between these conditions and traffic accidents among a sample of ecuadorian bus drivers.

we conducted a cross-sectional study from september 2019 to january 2020 among 340 male professional bus drivers in the city of guayaquil, ecuador. to be included in the study, participants were required to be male, have an unexpired professional driver's license, as well as being currently enrolled at any local transformational company. individuals who did not met the inclusion criteria, or who declined voluntary participation were excluded from the study. we screened 340 male professional bus drivers whose mean age was 44.3. we analyzed demographic and clinical variables including age, educational level, associated comorbidities (hypertension and diabetes), years as a professional driver, and number of accidents and near-accidents while working. accidents were defined as a collision involving the vehicle in which the participant was the driver and another vehicle or stationary obstruction. near-accidents were defined as unplanned events involving the driver that did not result in injury but had the potential to do so. we used stop questionnaire to assess four questions related to snoring, tiredness during daytime, observed apnea, and high blood pressure (stop), and the bang aspect for screening bmi ≥ 35, age ≥ 50, neck circumference \> 40 cm and male gender. also, we used epworth sleepiness scale (ess) to assess excessive daytime sleepiness (eds).

Eligibility criteria:
inclusion criteria: * male * have an unexpired professional driver's license * being currently enrolled at any local transformational company exclusion criteria: * not meeting inclusion criteria * declined voluntary participation

Keywords: sleep apnea daytime sleepiness accidents bus drivers